


Singapore's HistoIndex introduces AI-based quantitative analysis in fibrosis assessment

11 August 2025 | News

FibroSIGHT™ Plus test enhances confidence in fibrosis assessment and supports more personalised and data-driven treatment decisions



Singapore-based HistoIndex, a pioneering leader in digital pathology solutions for chronic liver disease, has announced the launch of FibroSIGHT™ Plus, its second Laboratory Developed Test (LDT) available in the United States.

Building on the foundation of FibroSIGHT™, which debuted just months earlier, FibroSIGHT™ Plus introduces an additional feature of automated quantitative analysis of fibrosis - a key advancement that enables more consistent and precise characterisation at diagnosis and tracking of fibrosis in patients with Metabolic Dysfunction-associated Steatohepatitis (MASH).

At the core of FibroSIGHT™ Plus is qFibrosis®, HistoIndex's proprietary AI-driven algorithm. By leveraging stain-free Second Harmonic Generation (SHG) imaging of MASH liver biopsies, qFibrosis® automatically quantifies multiple fibrosis-related collagen architectural and morphological features detected by SHG in various spatial zones of a liver biopsy and translates them into a single value or stage for fibrosis. The result is fibrosis expressed on a continuous scale, rather than in discrete categories. This allows more detailed insights into the disease severity and offers clinicians a sensitive tool with which to better characterise individual patients at diagnosis and to monitor subtle changes in their disease over time.

FibroSIGHT™ Plus marks another advancement in HistoIndex's efforts to integrate its digital pathology solutions into routine

patient care. With more innovations underway, HistoIndex continues to push the boundaries of what's possible in improving outcomes for patients with MASH.